Multiple myeloma is a cancer of the plasma cells that are found in the bone marrow.¹

It is the second most prevalent blood cancer after non-Hodgkin’s lymphoma, affecting approximately 7,000 Canadians in 2011, with the average age of diagnosis being 62 years for men and 61 years for women.²

Myeloma makes up 1.3% of all new cancer cases in Canada and 1.8% of all cancer deaths.²

Janssen provides an injection medication for the treatment of multiple myeloma.

 

Prostate cancer remains the most common cancer diagnosed in men, with an estimated 23,600 Canadian men diagnosed in 2014. ¹

The death rate has been declining significantly by almost 4% per year between 2001 and 2009, likely due to detecting prostate cancer earlier and to better treatment options.¹

Janssen provides an oral medication for the treatment of metastatic prostate cancer.

Anemia is a condition caused by a low level of healthy red blood cells (RBCs).¹ Cancer or cancer treatment (such as chemotherapy or radiation therapy) can affect the bone marrow so that it doesn’t make enough healthy red blood cells.¹

Anemia can cause a variety of symptoms such as fatigue, dizziness, and shortness of breath.¹

Janssen provides an injection medication for the treatment of anemia caused by chemotherapy for certain types of cancer.

Lymphoma is a cancer of the lymphatic system. When lymphoma occurs, some of the cells in the lymphatic system grow abnormally and out of control. Because there is lymph tissue throughout the body, the cancer cells may spread to other organs, or even into the bone.¹

Each year in Canada, more than 8,800 men and women are diagnosed with lymphoma and over 3,000 die from this disease.²

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in the Western world. It can be described as both leukemia and lymphoma because it is a cancer of the blood (leukemia) and because it originates in the lymphatic system (lymphoma).³

Janssen provides an oral medication for the treatment of CLL.